COST-EFFECTIVENESS ANALYSIS OF NIVOLUMAB FOR THE ADJUVANT TREATMENT OF PATIENTS WITH RESECTED ESOPHAGEAL CANCER (EC) OR GASTROESOPHAGEAL JUNCTION CANCER (GEJC) IN CANADA

被引：0
|
作者：
Amadi, A. [1 ]
Toor, K. [2 ]
Keeney, E. [3 ]
Thom, H. [4 ]
Singh, P. [5 ]
Kim, I [6 ]
Mameri, E. [7 ]
机构：
[1] Bristol Myers Squibb, Uxbridge, BC, Canada
[2] Precis Xtract, Vancouver, BC, Canada
[3] Univ Bristol, Bristol, Avon, England
[4] Univ Bristol, GLS, Bristol, Avon, England
[5] Bristol Myers Squibb, Lawrenceville, NJ USA
[6] Bristol Myers Squibb, Princeton, NJ USA
[7] Bristol Myers Squibb, St Laurent, PQ, Canada
来源：
VALUE IN HEALTH | 2022年 / 25卷 / 01期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
POSA39
引用
收藏
页码：S40 / S40
页数：1
相关论文
共 50 条
  • [1] A COST-EFFECTIVENESS ANALYSIS (CEA) OF ADJUVANT NIVOLUMAB FOR PATIENTS WITH RESECTED ESOPHAGEAL CANCER (EC) OR GASTROESOPHAGEAL JUNCTION CANCER (GEJC) IN FRANCE
    Paul, C.
    Massettti, M.
    Cotte, F. E.
    Moreau, R.
    Kassahun, S.
    Singh, P.
    Kim, I
    Gaudin, A. F.
    Leleu, H.
    [J]. VALUE IN HEALTH, 2022, 25 (12) : S180 - S180
  • [2] DEVELOPING A COST-EFFECTIVENESS ANALYSIS FOR NIVOLUMAB FOR THE ADJUVANT TREATMENT OF PATIENTS WITH RESECTED ESOPHAGEAL CANCER (EC) OR GASTROESOPHAGEAL JUNCTION CANCER (GEJC) IN THE ABSENCE OF OVERALL SURVIVAL DATA
    Amadi, A.
    Toor, K.
    Keeney, E.
    Thom, H.
    Singh, P.
    Kim, I
    Venkatachalam, M.
    [J]. VALUE IN HEALTH, 2022, 25 (01) : S67 - S67
  • [3] A Cost-Effectiveness Analysis of Adjuvant Nivolumab for Patients with Resected Esophageal Cancer or Gastroesophageal Junction Cancer in France
    Casabianca, Paul
    Massetti, Marc
    Cotte, Francois-Emery
    Moreau, Romain
    Kassahun, Sarah
    Singh, Prianka
    Kim, Inkyu
    Gaudin, Anne-Francoise
    Piessen, Guillaume
    Leleu, Henri
    [J]. PHARMACOECONOMICS-OPEN, 2024, 8 (05) : 689 - 699
  • [4] NUMBER NEEDED TO TREAT ANALYSIS OF NIVOLUMAB VERSUS SURVEILLANCE FOR THE ADJUVANT TREATMENT OF PATIENTS WITH RESECTED ESOPHAGEAL CANCER (EC) OR GASTROESOPHAGEAL JUNCTION CANCER (GEJC)
    Singh, P.
    Kassahun, S.
    Toor, K.
    Kim, I
    Kakehi, S.
    Estella-Perez, E.
    Venkatachalam, M.
    [J]. VALUE IN HEALTH, 2022, 25 (07) : S387 - S387
  • [5] HEALTHCARE RESOURCE UTILIZATION (HCRU) OF PATIENTS WITH RESECTED ESOPHAGEAL CANCER OR GASTROESOPHAGEAL JUNCTION CANCER (EC/GEJC) RECEIVING ADJUVANT NIVOLUMAB TREATMENT VERSUS PLACEBO
    Lawrance, R.
    Singh, P.
    Leso, A.
    Moreno-Koehler, A.
    Padilla, B.
    Sun, X.
    Taylor, F.
    Blum, S.
    [J]. VALUE IN HEALTH, 2021, 24 : S34 - S35
  • [6] Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer
    Kelly, Ronan J.
    Ajani, Jaffer A.
    Kuzdzal, Jaroslaw
    Zander, Thomas
    Van Cutsem, Eric
    Piessen, Guillaume
    Mendez, Guillermo
    Feliciano, Josephine
    Motoyama, Satoru
    Lievre, Astrid
    Uronis, Hope
    Elimova, Elena
    Grootscholten, Cecile
    Geboes, Karen
    Zafar, Syed
    Snow, Stephanie
    Ko, Andrew H.
    Feeney, Kynan
    Schenker, Michael
    Kocon, Piotr
    Zhang, Jenny
    Zhu, Lili
    Lei, Ming
    Singh, Prianka
    Kondo, Kaoru
    Cleary, James M.
    Moehler, Markus
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (13): : 1191 - 1203
  • [7] PHARMACOECONOMIC ANALYSIS OF ADJUVANT NIVOLUMAB FOR PATIENTS WITH RESECTED ESOPHAGEAL OR GASTROESOPHAGEAL JUNCTION CANCER IN SWITZERLAND
    Oniangue-Ndza, C.
    Strittmatter, G.
    Lucas, A.
    Wilson, M.
    Kassahun, S.
    Singh, P.
    [J]. VALUE IN HEALTH, 2022, 25 (12) : S95 - S95
  • [8] Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiation therapy (CRT): First results of the CheckMate 577 study
    Kelly, R. J.
    Ajani, J. A.
    Kuzdzal, J.
    Zander, T.
    Van Cutsem, E.
    Piessen, G.
    Mendez, G.
    Feliciano, J. L.
    Motoyama, S.
    Lievre, A.
    Uronis, H.
    Elimova, E.
    Grootscholten, C.
    Geboes, K.
    Zhang, J.
    Zhu, L.
    Lei, M.
    Kondo, K.
    Cleary, J. M.
    Moehler, M.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 : S1193 - S1194
  • [9] Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiotherapy (CRT): 14-month follow-up of CheckMate 577
    Moehler, M.
    Ajani, J. A.
    Kuzdzal, J.
    Zander, T.
    Van Cutsem, E.
    Piessen, G.
    Mendez, G.
    Feliciano, J.
    Motoyama, S.
    Lievre, A.
    Uronis, H.
    Elimova, E.
    Grootscholten, C.
    Geboes, K.
    Zhang, J.
    Soleymani, S.
    Lei, M.
    Kondo, K.
    Cleary, J.
    Kelly, R. J.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S1045 - S1046
  • [10] Adjuvant nivolumab (NIVO) in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiotherapy (CRT): expanded efficacy and safety analyses from CheckMate 577
    Zander, T.
    Kelly, R. J.
    Ajani, J. A.
    Kuzdzal, J.
    van Cutsem, E.
    Piessen, G.
    Mendez, G.
    Feliciano, J.
    Motoyama, S.
    Lievre, A.
    Uronis, H.
    Elimova, E.
    Grootscholten, C.
    Geboes, K.
    Zhang, J.
    Soleymani, S.
    Lei, M.
    Singh, P.
    Cleary, J. M.
    Moehler, M.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 80 - 81
12345